Citation Impact
Citing Papers
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Platelet Reactivity in Male Smokers Following the Acute Consumption of a Flavanol-Rich Grapeseed Extract
2007
CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: Is clinical testing helpful?
2012
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
2006
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2007
Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention
2012
Newer Pharmacotherapy in Patients Undergoing Percutaneous Coronary Interventions: A Guide for Pharmacists and Other Health Care Professionals
2006
Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel
2007
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
Effects of cranberry juice consumption on vascular function in patients with coronary artery disease
2011
Genetic polymorphisms of the platelet receptors P2Y12, P2Y1 and GP IIIa and response to aspirin and clopidogrel
2006
Structurally related (−)-epicatechin metabolites in humans: Assessment using de novo chemically synthesized authentic standards
2011
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study
2011
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period
2009
A Critical Evaluation of Influence of Ethanol and Diet on Salsolinol Enantiomers in Humans and Rats
2009
Nuts, hypertension and endothelial function
2011
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013 Standout
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
2012
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
2007
Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes
2013
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
2010
Nucleotide signalling during inflammation
2014 StandoutNature
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis
2010
Chocolate consumption in relation to blood pressure and risk of cardiovascular disease in German adults
2010
Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention††Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker’s bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida, and received lecture fees from Bristol Myers Squibb. Dr. Montalescot has been a consultant for and/or received research grants from Sanofi-Aventis.
2007
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Health effects of green tea catechins in overweight and obese men: a randomised controlled cross-over trial
2011
Variability in Individual Responsiveness to Clopidogrel
2007
Bivalirudin during Primary PCI in Acute Myocardial Infarction
2008 Standout
Effects of sugar-sweetened and sugar-free cocoa on endothelial function in overweight adults
2009
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
2010
New Antithrombotic Drugs
2012
Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain
2010
Bioactive Natural Constituents from Food Sources—Potential Use in Hypertension Prevention and Treatment
2013
Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension
2008
Effects of tea intake on blood pressure: a meta-analysis of randomised controlled trials
2014
Clopidogrel: A Case for Indication-Specific Pharmacogenetics
2012
Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis
2011
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome
2009
Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response
2012
Acrylamide: Review of Toxicity Data and Dose-Response Analyses for Cancer and Noncancer Effects
2006
Antiplatelet therapy: Controversial aspects
2011
Human CYP2E1 mediates the formation of glycidamide from acrylamide
2008
The changing landscape of atherosclerosis
2021 StandoutNature
Influence of the paraoxonase‐1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta‐analysis
2012
Glucuronidated and sulfated metabolites of the flavonoid quercetin prevent endothelial dysfunction but lack direct vasorelaxant effects in rat aorta
2008
Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects
2011
The Pictet–Spengler Reaction in Nature and in Organic Chemistry
2011 Standout
Cocoa flavanols: effects on vascular nitric oxide and blood pressure
2010
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
2013
Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial
2008
Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response
2011
Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients
2013 StandoutNobel
Risk-Benefit Considerations of Mitigation Measures on Acrylamide Content of Foods – A Case Study on Potatoes, Cereals and Coffee
2008
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention
2011
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
2012
Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials
2008
Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and Activation
2012
Chronotherapy With Low-Dose Aspirin for Prevention of Complications in Pregnancy
2012
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention
2011
Effect of Cocoa Products on Blood Pressure: Systematic Review and Meta-Analysis
2009
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial
2011 Standout
A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
2006
Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes
2009
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
2008
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction
2012
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
2008
Antiplatelet Drugs
2012
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
2011
Pharmacology of Antiplatelet Agents
2013
Antiplatelet Drugs
2008
Vascular protection by dietary polyphenols
2004
Comparative Effectiveness of Clopidogrel in Medically Managed Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction
2014
Flavonoid-Rich Cocoa Consumption Affects Multiple Cardiovascular Risk Factors in a Meta-Analysis of Short-Term Studies
2011
Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: A systematic review and meta-analysis
2012
ABCB1 C3435T Polymorphism and Response to Clopidogrel Treatment in Coronary Artery Disease (CAD) Patients: A Meta-Analysis
2012
Black tea consumption dose-dependently improves flow-mediated dilation in healthy males
2009
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
2010
The stereochemical configuration of flavanols influences the level and metabolism of flavanols in humans and their biological activity in vivo
2010
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?
2011
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
2008
The paraoxonase‐1 pathway is not a major bioactivation pathway of clopidogrelin vitro
2012
The gain‐of‐function variant allele CYP2C19*17: a double‐edged sword between thrombosis and bleeding in clopidogrel‐treated patients
2011
Plant Polyphenols: Chemical Properties, Biological Activities, and Synthesis
2011 Standout
Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis
2007
Impact of Genetic Polymorphisms and Drug – Drug Interactions on Clopidogrel and Prasugrel Response Variability
2010
Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis
2011
Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement
2006
Blood Pressure Is Reduced and Insulin Sensitivity Increased in Glucose-Intolerant, Hypertensive Subjects after 15 Days of Consuming High-Polyphenol Dark Chocolate13
2008
Sustained Benefits in Vascular Function Through Flavanol-Containing Cocoa in Medicated Diabetic Patients
2008
The effect of green tea on blood pressure and lipid profile: A systematic review and meta-analysis of randomized clinical trials
2014
Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19
2012
Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients
2009
Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials
2012
CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events
2011
Predicting Clopidogrel Response Using DNA Samples Linked to an Electronic Health Record
2011
Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade
2012
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis
2010
Hydroxycinnamic Acids as DNA‐Cleaving Agents in the Presence of CuII Ions: Mechanism, Structure–Activity Relationship, and Biological Implications
2009
Kinetics of Elimination of Urinary Metabolites of Acrylamide in Humans
2006
Dietary flavonoids: Role of (−)-epicatechin and related procyanidins in cell signaling
2011
High Doses of Clopidogrel to Overcome Genetic Resistance
2011
Calculations of dietary exposure to acrylamide
2004
Effect of Paraoxonase-1 Polymorphism on Clinical Outcomes in Patients Treated With Clopidogrel After an Acute Myocardial Infarction
2011
Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment<SUBTITLE>The ISAR-REACT 2 Randomized Trial</SUBTITLE>
2006
Milk decreases urinary excretion but not plasma pharmacokinetics of cocoa flavan-3-ol metabolites in humans
2009
A review of mechanisms of acrylamide carcinogenicity
2006
Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention
2008
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting
2011
Urinary acrylamide metabolites as biomarkers for short-term dietary exposure to acrylamide
2006
The CYP2C19*17 variant is not independently associated with clopidogrel response
2013
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation
2009
Acrylamide in children – exposure assessment via urinary acrylamide metabolites as biomarkers
2008
Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention
2012
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis
2010
Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study
2010
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Effect of Early, Pre-Hospital Initiation of High Bolus Dose Tirofiban in Patients With ST-Segment Elevation Myocardial Infarction on Short- and Long-Term Clinical Outcome
2010
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response
2012
Acrylamide exposure and incidence of breast cancer among postmenopausal women in the Danish Diet, Cancer and Health Study
2008
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement
2010
Flavonols and cardiovascular disease
2010
Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis
2007
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
2017 Standout
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
2011
Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention
2011
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention
2012
Antiplatelet agents for the treatment and prevention of atherothrombosis
2011
Human exposure and internal dose assessments of acrylamide in food
2004
Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness
2011
Effect of cocoa flavanols and exercise on cardiometabolic risk factors in overweight and obese subjects
2008
Acute dark chocolate and cocoa ingestion and endothelial function: a randomized controlled crossover trial
2008
Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine
2013
The Pharmacogenetics and Pharmacodynamics of Clopidogrel Response
2008
Relationships between biomarkers of exposure and toxicokinetics in Fischer 344 rats and B6C3F1 mice administered single doses of acrylamide and glycidamide and multiple doses of acrylamide
2006
Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection
2010
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
2012
Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers
2010
Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention
2008
Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non–ST-elevation acute coronary syndromes managed with an early invasive strategy
2008
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 Standout
Dietary (Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of Protective Effects Against Chronic Diseases
2012 Standout
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
Consumption of cocoa flavanols results in acute improvements in mood and cognitive performance during sustained mental effort
2009
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)
2011
Acrylamide and 5-hydroxymethylfurfural (HMF): A review on metabolism, toxicity, occurrence in food and mitigation strategies
2010 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Novel High-Throughput Assay for Antioxidant Capacity against Superoxide Anion
2009
Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy
2006
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
2008
Dietary Acrylamide Intake and Brain Cancer Risk
2009
Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel
2006
Association of TRIM22 with the Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection
2010
Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement
2011
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary
2014
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies
2010
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
Cytochromes P450 Catalyze Both Steps of the Major Pathway of Clopidogrel Bioactivation, whereas Paraoxonase Catalyzes the Formation of a Minor Thiol Metabolite Isomer
2011
Procyanidin Dimers Are Metabolized by Human Microbiota with 2-(3,4-Dihydroxyphenyl)acetic Acid and 5-(3,4-Dihydroxyphenyl)-γ-valerolactone as the Major Metabolites
2009
Abciximab in Patients With Acute ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading
2009
Impact of Genetic Variants on Post-Clopidogrel Platelet Reactivity in Patients After Elective Percutaneous Coronary Intervention
2011
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Influence of Thermal Processing Conditions on Acrylamide Generation and Browning in a Potato Model System
2006
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post–Myocardial Infarction Patients
2011
A circadian gene expression atlas in mammals: Implications for biology and medicine
2014 Standout
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity
2016 Standout
Clopidogrel Pharmacogenomics and Risk of Inadequate Platelet Inhibition: US FDA Recommendations
2009
Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets
2005
Cocoa and Cardiovascular Health
2009
Interferon-Stimulated Genes: A Complex Web of Host Defenses
2014 StandoutNobel
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
2012
Coexisting Polymorphisms of P2Y12 and CYP2C19 Genes as a Risk Factor for Persistent Platelet Activation With Clopidogrel
2008
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
2007
Impact of pH on the Kinetics of Acrylamide Formation/Elimination Reactions in Model Systems
2006
Differing Administration Time-Dependent Effects of Aspirin on Blood Pressure in Dipper and Non-Dipper Hypertensives
2005
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
2010
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)
2011
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention
2005
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
2007
Part 8: Post–Cardiac Arrest Care
2015 Standout
Superoxide Ion: Generation and Chemical Implications
2016 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Discharge Counseling for Patients with Heart Failure or Myocardial Infarction: A Best Practices Model Developed by Members of the American College of Clinical Pharmacy's Cardiology Practice and Research Network Based on the Hospital to Home ( H 2 H ) Initiative
2013
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
2015 Standout
The acute effect of green tea consumption on endothelial function in healthy individuals
2008
Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events
2012
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
2010
Prolonging healthy aging: Longevity vitamins and proteins
2018
Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes
2010
Pyrolytic acrylamide formation from purified wheat gluten and gluten‐supplemented wheat bread rolls
2005
Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose
2008
Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial
2010
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
2008
Polyphenols and Human Health: The Role of Bioavailability
2021 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2011
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Clopidogrel Response Variability and Future Therapies
2006
Weekend versus Weekday Admission and Mortality from Myocardial Infarction
2007 Standout
Hydroxymethylfurfural, A Versatile Platform Chemical Made from Renewable Resources
2013 Standout
Clinical, Pharmacokinetic, and Pharmacogenetic Determinants of Clopidogrel Resistance in Korean Patients with Acute Coronary Syndrome
2011
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2013
Works of Dirk Taubert being referenced
Preferential Upregulation of Interferon-α Subtype 2 Expression in HIV-1 Patients
2009
Reaction rate constants of superoxide scavenging by plant antioxidants
2003
Effects of Low Habitual Cocoa Intake on Blood Pressure and Bioactive Nitric Oxide
2007
Impact of P-glycoprotein on clopidogrel absorption
2006
Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action
2004
Identification of the Endogenous Key Substrates of the Human Organic Cation Transporter OCT2 and Their Implication in Function of Dopaminergic Neurons
2007
Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction
2008
Pharmacokinetics of clopidogrel after administration of a high loading dose
2004
Paraoxonase-1 is a major determinant of clopidogrel efficacy
2010
Nitric Oxide Formation and Corresponding Relaxation of Porcine Coronary Arteries Induced by Plant Phenols: Essential Structural Features
2002
Increased Interferon Alpha Expression in Circulating Plasmacytoid Dendritic Cells of HIV-1-Infected Patients
2008
Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel
2009
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
2011
A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite
2005
Dietary Sources and Antioxidant Effects of Ergothioneine
2007
Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel
2005
Toxicokinetics of Acrylamide in Humans after Ingestion of a Defined Dose in a Test Meal to Improve Risk Assessment for Acrylamide Carcinogenicity
2006
In vivoRole of CytochromeP450 2E1 and Glutathione-S-Transferase Activity for Acrylamide Toxicokinetics in Humans
2009
Influence of Processing Parameters on Acrylamide Formation during Frying of Potatoes
2004
Effect of cocoa and tea intake on blood pressure: a meta-analysis.
2007
Association of rheumatoid arthritis with ergothioneine levels in red blood cells: a case control study.
2006